MedTrace Logo

Study of LM-102 in Patients With Advance Solid Tumors

NCT05008445 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-03-09

No results posted yet for this study

Summary

This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2). It is being tested in advanced solid tumors including gastric cancer/gastroesophageal junction adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, esophageal adenocarcinoma and ovarian mucous carcinoma.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

LM-102 Injection

LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.

COMBINATION_PRODUCT

LM-102 Injection combined with SOC

LM-102 Injection with appropriate dose level(s), combined with SOC.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • LaNova Medicines Development Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tianshu Liu · Shanghai Zhongshan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2023-02-08
Completion
2023-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008445 on ClinicalTrials.gov